Eli Lilly Looking to Remove Obstacles to GLP-1 Drugs With Direct Sales -- Market Talk
Dow Jones
Oct 31, 2025
1329 ET - Eli Lilly's direct channel sales are reducing obstacles to access GLP-1 drugs, helping it grow the total market, the company says on its analyst call. "There is significant demand in the consumer segment related to finding ways to get outside some of the frictions in the health care system," Lily USA President Ilya Yuffa says. "We're seeing significantly more volume go through a direct-to-consumer platform with Lilly Direct." The company also said this week patients would be able to pick up Zepbound vials at Walmart. That accessibility is "an important element for us to expand the ability for patients to get treated," Yuffa says. (nicholas.miller@wsj.com)
(END) Dow Jones Newswires
October 30, 2025 13:29 ET (17:29 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.